Items stated in the management plan
Partially revisedThis document does not state the plan name, plan period, or numerical targets.
To strategically review the development pipeline and optimize the allocation of management resources in light of recent changes in the drug discovery business environment. After comprehensively considering the clinical trial results and other factors relating to similar development programs ahead of these programs, the Company determined that the feasibility of obtaining regulatory approval had declined significantly. For BP1209, the sharp increase in the number of peptides incorporated into the product caused manufacturing costs to rise sharply, making competition with mRNA vaccines difficult.
| Item | Details |
|---|---|
| Progress against the plan | Partially revised |
| Key initiatives | Continue to advance the clinical development of the iPS cell-derived CAR-T cell therapy (BP2202) as a core initiative |
| Reason for revision or withdrawal | To strategically review the development pipeline and optimize the allocation of management resources in light of recent changes in the drug discovery business environment. After comprehensively considering the clinical trial results and other factors relating to similar development programs ahead of these programs, the Company determined that the feasibility of obtaining regulatory approval had declined significantly. For BP1209, the sharp increase in the number of peptides incorporated into the product caused manufacturing costs to rise sharply, making competition with mRNA vaccines difficult. |
| Risks identified | The leading development programs may fail to demonstrate the efficacy initially expected of them to a sufficient degree, resulting in the discontinuation of development, The possibility of having a clear competitive advantage capable of overturning the results of the leading development programs may be limited, A sharp increase in manufacturing costs due to an increase in the number of peptides incorporated into the product, Competition with mRNA vaccines whose manufacturing costs have been optimized may become difficult |
| Publication date | 14 May 2026 |
Items this document does not state (20)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To optimize the allocation of management resources in light of recent changes in the drug discovery business environment. Based on the clinical trial results of similar development programs ahead of these programs, among other factors, the Company determined that the feasibility of obtaining regulatory approval and the likelihood of having a clear competitive advantage capable of overturning the results of the leading programs had declined significantly. For BP1209, competition with mRNA vaccines became difficult because the increase in the number of peptides incorporated into the product raised manufacturing costs.